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ABSTRACT 
Objectives 
Haemorrhoidal disease is a common condition causing considerable distress to individuals 
and significant cost to the health care service. This paper explored the cost-effectiveness of 
stapled haemorrhoidopexy (SH) compared with the standard non-surgical intervention, 
rubber band ligation (RBL), for grade II symptomatic circumferential haemorrhoids. 
 
Methods 
An economic evaluation alongside a randomised controlled trial conducted between October 
2002 to February 2005.  Adults were recruited from a single surgical centre in Scotland and 
randomised to either SH or RBL.  The same surgeon performed all procedures and 
investigators were blinded until analyses was completed.  Primary outcomes measured at 52 
weeks were cumulative costs to the NHS, clinical diagnosis of recurrence and quality 
adjusted life years (QALYs).   
 
Results 
60 symptomatic men and women with confirmed clinical diagnosis of grade II symptomatic 
haemorrhoids were randomised. Loss to follow-up was up to 10% at 52 weeks.   
 
The mean cost for SH was greater than RBL (mean difference - £1483, 95% CI £1339 to 
£1676); disease recurrence was lower (OR 0.18, 95% CI 0.03 to 0.86); and there was no 
evidence of a statistically significant difference in QALYs (-0.014, 95% CI –0.076 to 0.051).  
SH was associated with a modest incremental cost per recurrence avoided at 12 months 
follow-up (£4945).  Based on current data it was considered highly unlikely to be cost-
effective in terms of incremental cost per QALY.   
 
Conclusions 
There is insufficient evidence about the cost-effectiveness of SH for grade II haemorrhoids to 
recommend its use in place of RBL.  Further information is needed from larger trials with a 
longer-term follow-up to inform subsequent economic evaluation.   
 
 
INTRODUCTION 
Haemorrhoidal disease is one of the commonest benign ano-rectal conditions and is 
associated with relapsing and remitting symptoms. The majority of patients (75%) diagnosed 
with second degree haemorrhoids require treatment within a few years1. Early intervention 
may avoid advanced disease and its associated complications. The current standard 
treatment for symptomatic grade II haemorrhoids, rubber band ligation (RBL), is readily 
available, can be performed as an out-patient procedure, is tolerated well and does not 
require general anaesthesia.1  As a consequence the cost per procedure is relatively low 
This technique, however, is associated with a treatment failure rate of more than 40%2,3 
 
and 
the return of symptoms will reduce quality of life and require lead to further costly treatment,   
Excisional haemorrhoidectomy (EH) is considered the ‘gold standard’ treatment for 
advanced (grade III and IV) haemorrhoids and remains the most commonly performed 
surgical intervention.4 A systematic review comparing EH with RBL has shown no significant 
difference in the clinical effectiveness for grade II haemorrhoids. Furthermore EH was shown 
to be associated with increased incidence of complications.5
 
  
Stapled haemorrhoidopexy is an alternative surgical intervention accepted and performed 
widely because of its clinical success.6,7,8  It shares a similar mechanism of action to RBL by 
addressing haemorrhoidal prolapse and bleeding whilst maintaining the presence of the anal 
cushions. It acts by relocating the haemorrhoidal cushions cranially into their original position 
by excising a strip of lower rectal mucosa (pain insensitive mucosa) and by interrupting the 
blood supply to the haemorrhoids. It is however more costly than RBL.  There is very limited 
literature evidence available comparing stapled haemorrhoidopexy with RBL for grade III and 
IV haemorrhoids.9
 
 and there is no data available for grade II haemorrhoids.  
In view of the relatively high recurrence rate for symptoms following RBL and the lack of 
comparative studies against stapled haemorrhoidopexy and the difference in treatment cost, 
we conducted a pilot study to compare these two techniques in a randomised controlled 
setting. This economic evaluation, conducted alongside the randomised controlled trial, 
sought to assess the cost-effectiveness of stapled haemorrhoidopexy compared with RBL 
for grade II symptomatic haemorrhoids.   
METHODS 
Description of trial 
The trial was a pragmatic randomised controlled trial comparing stapled haemorrhoidopexy 
with rubber band ligation for grade 2 haemorrhoids. Further details of the trial are reported 
elsewhere9
 
 but in brief 60 participants were recruited from one centre in Aberdeen Scotland, 
between October 2002 and February 2005, and randomised to either stapled 
haemorrhoidopexy (n = 30) or RBL (n = 30). Patients with associated colonic malignancy, 
symptomatic anal sphincter damage or ano-rectal sepsis were excluded from the trial.  
Written informed consent was obtained from all eligible participants and the Grampian 
Research Ethics Committee approved the study (Ethics committee approval code – GREC 
01/0297).  Participants who were randomised to stapled haemorrhoidopexy would, if 
symptoms had not resolved, be eligible for two repeat procedures.  This was assessed at a 6 
week, a 26 or a 52 week follow-up or at a re-presentation.  RBL patients were eligible for a 
maximum of four repeat procedures. Longer-term recurrence rates for both treatments were 
assessed at 40.7 (±6.3) months. All analyses were conducted on an intention to treat basis.  
Measurement of costs 
Costs included health care resource costs (from the perspective of the NHS) for initial 
treatment and follow up events, both for secondary care and primary care. As detailed below 
resource usage was recorded as part of the trial for each individual patient and wherever 
possible, unit costs for these resources were identified at the individual patient level.  At 
initial treatment visits and all scheduled follow up visits at 6, 26 and 52 weeks hospital 
resource use was recorded using data collection forms for each patient.  Information 
recorded included the anaesthetic time (for stapled haemorrhoidopexy), length of time for the 
procedures, recovery time and post procedure stay in ward, duration of any in-patient stay 
and medications.  Details of any unscheduled hospital visits, primary care contacts, over the 
counter medications and prescriptions were obtained from a self-reported patient 
questionnaire completed at 6, 26 and 52 weeks post randomisation.  Details of the methods 
used to derive resource used to provide the two procedures are described below.  
 
Operative Costs 
The resources required for RBL were based on the procedure being performed in an 
outpatient setting.  Details of the staff involved were recorded on a case report form 
completed at the time of surgery.  Also included on this form were details of the post 
discharge medication and the use of consumables (disposable rubber band applicator, 
disposable proctoscope) required for the procedure.   
 Resource costs for stapled haemorrhoidopexy included theatre running costs, assumed to 
include an element for recovery facilities, were derived from published sources10 to establish 
a theatre cost.  The cost of staff involved in theatre were based upon the number and grade 
specific health care professionals necessary for each procedure.  Operative costs relating to 
surgical repair of haemorrhoids (including consumables, drugs, equipment and sterilisation) 
for the two interventions studied were sourced from the hospital pharmacy and measured 
prospectively.  The cost of reusable items were converted into annual costs (when it was 
believed the equipment would last more than 1 year using a discount rate of 3.5%11
 
). This 
value was divided by the amount of time the equipment would be used used in a year to give 
a cost per patient.   
In the instance that a patient experienced a recurrence, the overall resource use of the 
repeat surgery was assumed to be the mean value of the original surgical procedure across 
all patients.  
 
A summary of the costs used in the analysis is provided in Table 1. All costs are at 
calculated in 2004 prices and inflated to 2006/7 prices using the hospital pay and prices 
inflation index.
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Effectiveness 
Clinical effectiveness was measured in terms of whether or not the treatment had failed over 
the 52 weeks following initial treatment. At the 52 week follow-up a clinical assessment was 
made using proctoscopy and symptom enquiry. This was performed by an experienced 
consultant colorectal surgeon who was blinded to the original intervention.  Further 
assessment of clinical effectiveness was undertaken at a mean follow-up of 40.7 (± 6.3) 
months. 
 
Quality of life was measured using the EQ-5D questionnaire. Each patient was asked to 
complete the EQ-5D at baseline, 3, 6, 26 and 52 weeks. Quality adjusted life years (QALYs) 
were calculated from the EQ-5D responses using UK population tariffs.13  Differences 
between groups were based on linear regression adjusting for the EQ-5D score at 
baseline.14
 
   
Cost-effectiveness 
The incremental cost per recurrence avoided was estimated by combining the estimates of 
incremental costs and the difference in recurrence rates.  Similarly, using the estimates of 
incremental cost and QALYs, the incremental cost per QALY was estimated.  No discounting 
of costs and effects was performed, as the time horizon was only one year.  Non-parametric 
Bootstrap methods were used for statistical inference on total costs, QALYs and cost per 
QALY because of skewed distributions.15
 
   
Sensitivity Analysis 
In economic evaluation sensitivity analysis is used to address concerns which might relate to 
such issues as whether the methods of estimating data influence the conclusions or whether 
data are generalisable to other settings.  In this analysis there is uncertainty about the 
magnitude of any difference in cost.  The total cost per patient was recalculated using 
alternative values for the procedure cost.  This was done separately for stapled 
haemorrhoidopexy and RBL. For stapled haemorrhoidopexy the initial procedure cost (and 
similarly the cost per re-treatment) was reduced by 25% and by 50%. For RBL, initial 
procedure cost (and cost per re-treatment) was increased by 50% and by 100%.   
 
With respect to the precision surrounding estimates of the incremental cost per recurrence 
avoided the cost effectiveness results were re-estimated using the extreme values of the 
95% confidence intervals for the difference in total costs and recurrence rates. This was 
done using best case and worst case scenarios for the stapled haemorrhoidopexy 
procedure. 
 
A further area addressed in the sensitivity analysis was the impact of imputing missing 
quality of life data.  In the base case analysis the mean difference in QALYs was estimated 
using information from those trial participants who had utility scores available at each time 
point.  The drawback of this approach is that a participant would be excluded if data for that 
participant were only available for only three of the four time points, approximately 10% of 
responses were missing.  A second approach was therefore also adopted.  In this, the 
missing data were imputed from the most recent previous score that was available. 
 
RESULTS 
A total of 69 patients were identified from clinic or direct access endoscopy, of which two 
patients were subsequently, deemed unsuitable (One recent RBL and another unsuitable for 
anaesthesia).   Details of the trial were presented to the remaining 67 patients, 66 of whom 
chose to participate. Of these, 64 were considered suitable for randomisation. Four patients 
were then excluded (one could not attend hospital due to personal commitment and three 
were not recruited for want of base line data due to technical reasons) leaving a total of 60 
eligible patients who were randomised (by computer) to either RBL or stapled 
haemorrhoidopexy.  Complete data were available for 54 patients at the end of the trial 
period (2 withdrew early, four moved and forwarding addresses were not obtainable before 
the final follow-up). The baseline characteristics and clinical outcomes for this trial are 
reported elsewhere.
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Health Care Costs 
The mean total cost per patient, both in aggregate and separately for each element of health 
care is presented in Table 2.   These are rounded to the nearest pound. The mean cost per 
patient treated using stapled haemorrhoidopexy was significantly higher than that for RBL 
(£1757 compared to £273).  Much of this difference can be attributed to the initial procedure 
cost which is relatively high for stapled haemorrhoidopexy (£1647 vs £102 for RBL) due to 
the cost of the disposable stapling gun (£336) along with drugs and staff costs incurred in 
theatre, plus the hospital stay requirement. 
 
Incremental Cost per Recurrence 
Recurrence rate at 52 weeks was significantly higher in the RBL treatment group than the 
stapling group [11 (41%), n =27, compared to 3 (11%), n = 27) OR 0.18 (95% CI 0.03, to 
0.86), P = 0.028). This gave an incremental cost per recurrence avoided from stapled 
haemorrhoidopexy of £4945.  At a mean follow-up of 40.7 (±6.3) months the recurrence 
rates were 12 out of 22 patients for whom data were available in the RBL group and 4 out of 
24 patients in the stapling group, OR 0.22 (95% CI 0.04, to 0.92).  This give an incremental 
cost per recurrence of £3917. This estimate excludes treatment costs incurred after the first 
year. 
 
Incremental cost per QALY 
Quality Adjusted Life Years and the EQ-5D scores at baseline and at 52 weeks are reported 
in Table 4.  Four patients in each treatment group had missing values for EQ-5D data at one 
or more time points. The mean value for QALYs was higher for the RBL patients than those 
treated with stapled haemorrhoidopexy although the confidence intervals were wide.  In 
terms of mean incremental cost per QALY, RBL dominated stapled haemorrhoidopexy (RBL 
was associated with lower mean cost and greater mean QALYs than the stapled 
haemorrhoidopexy group).   
 
Sensitivity analysis 
The results of the sensitivity analyses described in the methods are presented in Table 3.  
Under each scenario for procedure costs and also for the best case scenario based on 
confidence intervals for costs, RBL was the dominant procedure in terms of the incremental 
cost per recurrence avoided.  
 
Table 5 shows that the base case results for incremental cost per QALY were also robust in 
terms of RBL being the dominant intervention for variations in procedure costs.  
 
DISCUSSION 
With stapled haemorrhoidopexy for grade II haemorrhoids we found that at 52 weeks there 
was a statistically significant reduction in recurrences which was associated with a relatively 
modest incremental cost per recurrence avoided, although it is a matter of judgement as to 
this additional benefit is worth the extra cost.  However, there was no evidence that this 
difference in the risk of recurrence translated into differences in quality of life.  Furthermore, 
it was unlikely that stapled haemorrhoidopexy would be considered cost-effective at 
threshold values for society’s willingness to pay for a QALY based upon the 12 month data.   
 
The population in the trial was representative of those seen in practice and were all treated 
by a single surgeon with considerable experience in performing both procedures.  Therefore, 
it might be expected that if there were benefits to stapled haemorrhoidopexy in terms of 
quality of life then these would be seen within this study.  However, the relatively small size 
of the RCT on which this economic evaluation was based would render the results 
imprecise.  Furthermore, the time horizon over which costs and effects were considered was 
only 52 weeks, although further information of recurrence rates was available for a mean 
follow-up of 40.7 months.  Given the finding of increased recurrences in the rubber band 
ligation arm the difference in cost might fall over a longer time horizon and that the quality of 
life associated with the rubber band ligation arm would be reduced.  Given that the benefits 
from stapled haemorrhoidopexy may persist into the future it is possible to consider under 
what circumstances stapled haemorrhoidopexy might be considered worthwhile.  For 
example, if society’s maximum value willingness to pay for a QALY was £20,00011 and the 
difference in cost was unchanged then stapled haemorrhoidopexy would need be associated 
with an average gain of 0.07 QALYs compared with RBL over the expected life time of a 
patient.  This might occur if, on average, patients who initially received RBL spent at least 
0.6 years more with a recurrence (and patients with a recurrence returned to their pre-
treatment quality of life).  Numerous factors, including the long-term performance of both 
procedures will affect estimates of cost-effectiveness but should differences in recurrence 
rates persist then it is possible that the cost-effectiveness of stapled haemorrhoidopexy  
might improve but further long-term data would need to incorporated into a well designed 
economic model to explore this fully.   
 
The results of the analysis were sensitive to the costs associated with stapled 
haemorrhoidopexy.  Changes in management as well as in equipment can result in 
improvements in the cost-effectiveness of this procedure. In terms of future research a 
further larger scale RCT would be required.  The design of this study might be informed by a 
modelling exercise in which value of information methods are used to determine an optimal 
design and sample size.   
 
CONCLUSIONS 
Based upon the data presented in this paper it is unlikely that stapled haemorrhoidopexy 
would be considered a cost-effectiveness treatment for grade II haemorrhoids and hence 
there is no basis to recommend its use in place of rubber band ligation.  However, the risk of 
recurrence at 52 weeks and at a mean follow-up of 40.7 months following surgery is lower.  
Further information is needed from larger trials with a longer term follow-up before this 
conclusion should be revisited.   
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Table 1 Unit Costs  
 Operative Event - Stapled haemorrhoidopexy Procedure 
 
Unit Cost 
 
Source  
 
 Operative event Equipment and Drugs £389.32 Hospital pharmacy 
 Cost per min in pre-op (anaesthetic room)  £1.47 15 
 Cost per min in theatre £3.37 15 
 Cost per min in recovery £0.29 15 
 Cost per min for theatre overheads £9.74 15 
    
 Hospital Stay Day case £28.19 10 
 In-patient £138.12 10 
   
 
 
 Operative Event - Rubber Band Ligation Procedure  
       
 Operative event Equipment and Drugs £26.97 Hospital pharmacy 
 Hospital Stay Out-patient £74.82 10 
    
 Post discharge events (for both Rubber Band Ligation and stapled haemorrhoidopexy) 
        
 Contact with health professionals 
GP visit £17.35 15 
Visits by nurse £11.93 15 
 Out-patient visits £74.82 15 
 Telephone consultation £20.60 15 
 GP home visit/out of hours visits £54.22 15 
    
 Sanitary pad £2.05 Chemist and Druggist 
  £0.00  
 Discharge medication Laxative £2.64 16 
 Antibiotic £0.67 16 
 haemorrhoidal cream  £7.32 16 
 Analgesic £1.84 16 
 Anaesthetic £1.52 16 
   16 
 Prescriptions Antihistamine £0.34 16 
 Analgesic £1.03 16 
 Laxative £2.52 16 
 Antibiotics £0.67 16 
 Anti-inflammatory £2.85 16 
 haemorrhoidal cream £5.81 16 
 Anti-fungal cream £2.58 16 
    
 Repeat RBL  Mean RBL  
 Repeat Stapled haemorrhoidopexy  Mean Stapling  
 Hospital Stay Day-case £28.19 10 
 In-patient £138.12 10 
 
Table 2 Mean health care costs per patient (costs rounded to nearest £) 
Mean cost per case*  Stapled 
haemorrhoidopexy 
(sd) 
RBL (sd) Mean 
difference* 
P 95% confidence 
interval 
N 30 30    
Valid N 30 30    
Procedure cost £1647 £102 -£1545 <0.000 -£1630 to –£1461 
 (-£227) (£0)    
      
Re-treatment cost £31 £64 £33 0.380 -£42 to £107 
 (-£174) (-£105)    
      
Discharge medication £18 £14 -£4 <0.000 -£5 to - £3 
 (-£2)  (-£2)    
      
Prescription costs £3 £1 -£2 0.122 -£4 to £0 
 (-£5)  (-£3)     
      
Primary care contacts £15 £4 -£12 0.053 -£24 to £0 
 (-£30.36)  (-£11)     
      
Secondary Care contacts £41 £91 £50 0.165 -£22 to £123 
 (-£121)  (-£152)     
      
TOTAL COST PER CASE 
£1,757 £273 -£1483 
<0.000 -£1676 to -
£1339† 
 (-£346)  (-£246)     
* costs are rounded to nearest £ pound. Summation errors may be attributed to rounding.  
†  based on the 2.5 and 97.5 percentile from the bootstrapping  
 
Table 3 Sensitivity analysis on increment al cost per recurrence avoided* 
Sensitivity analysis Scenario RBL Stapled 
haemorrhoidopexy 
Incremental cost Incremental 
recurrence 
avoided 
Incremental cost 
per recurrence 
avoided 
Adjustment to 
procedure cost 
Cost of Stapled haemorrhoidopexy 25% 
lower; Base case value for RBL 
£273 £1337 £1064 0.296 £3595 
Cost of Stapled haemorrhoidopexy 50% 
lower; Base case value for RBL 
£273 £917 £644 0.296 £922 
Cost of RBL 50% higher; Base case 
value for stapled haemorrhoidopexy 
£356 £1757 £1401 0.296 £4732 
Cost of RBL 100% higher; Base case 
value for Stapled haemorrhoidopexy 
£439 £1757 £1318 0.296 £4451 
Extreme value of 
confidence interval 
Best case scenario for Stapled 
haemorrhoidopexy 
£439 £917 £478 0.395 ** £1210 
Worst case scenario for Stapled 
haemorrhoidopexy 
£273 £1757 £1483 0.057 £26,008 
 * all costs rounded to nearest £ pound 
**  based on extreme values from confidence intervals
Table 4 EQ-5D and estimated Quality adjusted life years* 
Scenario Treatment EQ-5D score QALYs(95% CI)*** 
  Baseline 6 weeks 26 weeks 52 Weeks  
Available data 
only** 
SH 0.75 0.87 0.88 0.85 0.863 
RBL 0.79 0.85 0.90 0.88 0.876 
Difference 0.041 0.027 0.038 0.059 -0.0135 (-0.067 to 0.066) 
Imputed data SH 0.73 0.84 0.86 0.83 0.866 
RBL 0.80 0.85 0.91 0.89 0.880 
Difference  0.065 0.011 0.026 0.026 -0.014 (-0.076 to 0.051) 
*  based on adjustment for baseline EQ-5D score 
** based on cases with complete data for all EQ-5D scores. RBL (n = 26) and Stapled 
haemorrhoidopexy (n =26) 
***  95% CI based on results of bootstrapping exercise 
 
 
Table 5 Incremental cost per QALY for the base case and sensitivity analyses 
Scenario Surgery Cost (£) QALYs Incremental cost per 
QALY 
Probability cost-effectiveness for different threshold values for society’s 
willingness to pay for a QALY 
    £10,000 £20,000 £30,000 £50,000 
QALYs based on cases with 
complete EQ-5D data 
 
SH £1757 0.863 Dominated 0.0% 1.2% 7.0% 17.8% 
RBL £273 0.876  100.0% 98.8% 93.0% 82.2% 
        
QALYs where missing EQ-5D data 
has been imputed 
SH £1757 0.866* Dominated 0.0% 0.5% 2.7% 9.9% 
RBL £273 0.880  100.0% 99.5% 97.3% 90.1% 
        
Costs of haemorrhoidopexy 75% of 
base case 
SH £1318 0.866* Dominated 0.1% 2.4% 7.6% 16.6% 
RBL £273 0.880  99.9% 97.6% 92.4% 83.4% 
        
Costs of haemorrhoidopexy 50% of 
base case 
SH £878 0.866* Dominated 1.3% 9.8% 16.6% 23.9% 
RBL £273 0.880  97.7% 91.2% 83.4% 76.1% 
        
SH = Stapled haemorrhoidopexy; RBL = Rubber band ligation 
* based on the mean value for RBL and the adjusted difference reported in Table 4 
 
